NCT04172753Recruiting
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac
Feasibility of Imaging and Radiotherapy on a Novel 1.5 T Hybrid Magnetic Resonance Imaging - Linear Accelerator System (MR-Linac)
Source: ClinicalTrials.gov · Last updated 21 Nov 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study investigates the feasibility of imaging and treatment on a novel 1.5 T MR-Linac radiotherapy hybrid device.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 472 (estimated)
- First submitted
- 4 Nov 2019
- Start date
- 9 May 2018
- Primary completion date
- 9 May 2022
- Lead sponsor
- University Hospital Tuebingen
- Diseases
- Prostate cancer, Head and neck cancer, Colorectal cancer, Liver and biliary tract cancer, Gastric and esophageal cancer
- NCT number
- NCT04172753
What you commit to
- Study type: Interventional
- Planned participants: 472
- From 9 May 2018 to the primary completion date, 9 May 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- contraindication for MRI (claustrophobia, metallic implants not applicable for MRI
Other
- pregnancy
Who the study is looking for
- existing indication for radiation therapy
- minimum age 18 years, no upper age limit
- capacity for consent
- Informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Tübingen, Department of Radiation Oncology Coordinator of this site? Confirm its status | Tübingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.